Advertisement
Advertisement
TOPIC

Biomedicine: Companies

Related Topics:
Biomedicine: Companies
Learn about China’s biomedical breakthroughs, from cutting-edge pharmaceuticals to life-saving research, driving global health innovation.
China steps up Alzheimer’s, Parkinson’s drug push, looks to TCM
Science

Biomedicine | China steps up Alzheimer’s, Parkinson’s drug push, looks to TCM

With the most cases of the two leading neurodegenerative diseases, and affected population rising as country ages, China needs to find new treatments.

China’s private sector

Akeso lung cancer drug trial raises hopes in US$20b market

Biomedicine: Industry Trends

China’s Innovent Biologics signs US$10.5b Pfizer deal for 12 cancer drug trials

videocam
Science

Chinese team uses supercomputer to cut drug screening time from years to seconds

AI platform that can screen vast library of chemical compounds opens up new frontiers in fight against cancer and infectious diseases.

videocam
Innovative drug research and development typically takes more than 10 years to yield results. Photo: Shutterstock
China’s private sector

China’s biotech boom drives surge in home-grown innovative drug approvals

Domestic firms dominate China’s drug approvals amid jump in spending and out-licensing deals as regulator speeds path to market.

China’s private sector

Insilico, US partner to build AI models predicting disease decades ahead

Tie-up combines Hong Kong-listed Insilico Medicine’s algorithms with Human Longevity’s genomic data to advance personalised health research.

Advertisement
Advertisement
Advertisement
Banking & finance

Hong Kong-listed firm uses AI to make nano-rockets to deliver life-saving drugs

METiS TechBio debuts on Hong Kong stock market as its CEO compares the drug design start-up to SpaceX for the pharmaceutical industry.

videocam
METiS TechBio debuts on Hong Kong stock market and raises HK$2.11 billion (US$269.5 million) from the sale of 201.23 million shares at HK$10.50 each. Photo: Jelly Tse
China’s private sector

China’s Hengrui seals US$15.2 billion deal with US pharmaceutical giant BMS

Company’s shares jump in Hong Kong and Shenzhen after tie-up that bolsters China’s growing drug innovation profile.

Artificial intelligence

ByteDance’s drug unit presents AI-designed therapies at global conferences

Chinese tech giant fields teams in Boston, Rio de Janeiro and Barcelona as its unit unveils frameworks and therapies powered by AI.

Hong Kong company reporting season

WuXi AppTec shares surge 14% in Hong Kong after record first-quarter earnings

The Chinese company’s revenue rose nearly 29 per cent to 12.44 billion yuan, while profit surged about 27 per cent to 4.65 billion yuan.

WuXi AppTec’s R&D centre in Shanghai. Photo: CFOTO/Future Publishing via Getty Images
United States

US FDA plans ultra-fast review of 3 psychedelic drugs after Trump directive

The recent moves on psychedelics reflect growing popular support for the mind-altering substances among Trump’s supporters.

US President Donald Trump holds an executive order about easing restrictions on mental health treatments, including ibogaine, which he signed, in the Oval Office of the White House on Saturday. Photo: Reuters
Banking & finance

Biotech-led boom as 8 China firms flock to Hong Kong’s thriving stock market

AI-powered drug developer Metis TechBio leads group that includes developers of autonomous driving technology and industrial robots.

China’s private sector

How China’s ‘landmark’ drug pricing guidelines could be a boon for biotech

State Council calls for ‘value-based pricing’ for innovative drugs, a move researchers said would benefit private healthcare players.

China’s private sector

Chinese drug makers take on Western dominance in US$16 billion Parkinson’s race

The future of treating brain diseases could lie in non-invasive technologies, according to Chongqing Haifu Medical Technology.

Hong Kong’s Tuen Mun Hospital has for the first time in the city used a non-invasive ultrasound procedure to treat a Parkinson’s disease patient with uncontrollable tremors. Photo: Handout
China’s private sector

China’s drug makers are speeding up – will AI be their secret weapon?

Chinese biotech firms are striking big global deals as drug makers, but could artificial intelligence take them to the next level?

Illustration by Henry Wong
Banking & finance

China healthcare stocks shine in Hong Kong amid Middle East turmoil

Hang Seng Healthcare Index outpaces broader market as Akeso, Innovent, Hansoh provide refuge for global investors.

Banking & finance

Everest’s US$250 million buy signals rising global appetite for China biotech

Sovereign wealth funds from Singapore and Abu Dhabi join Chinese state capital as cross-border biotech licensing reaches record highs.

Advertisement
Advertisement
Advertisement
Biomedicine: Geopolitics

Global drug makers face pricing pressure as China targets affordable healthcare

As pharmaceutical firms navigate China’s aggressive pricing reforms, their profits could be squeezed further this year.

5
A pharmaceutical production line in Meishan, China. Photo: Costfoto/NurPhoto via Getty Images
Banking & finance

Stricter Chinese scrutiny of offshore vehicles a blow for tech IPO candidates

Mainland’s stock market watchdog is discouraging establishment of ‘red-chip-structured’ companies in sensitive industries.

Banking & finance

Chinese company to use AI-powered testing to boost profits and fast-track IVF

China’s falling fertility rate sees spike in demand for assisted reproduction as biotech firm raises US$101 million from Hong Kong listing.

videocam
Banking & finance

Insilico Medicine signs AI drug development deal with Eli Lilly

Reaching development, regulatory and commercial milestones could see value of deal hit around US$2.75 billion.

Life Star2, Insilico’s automation lab. Photo: Handout
China’s private sector

Li Ka-shing’s CK Life unit eyes China fast track for cancer vaccine pipeline

Sequencio, CK Life’s new Hong Kong unit, is advancing about 20 cancer vaccine projects as China pathway offers faster route to human trials.

In China, investigator-initiated trials allow drug makers to generate human clinical data “faster” than the conventional regulatory process. Photo: Shutterstock
Medicine

China biotech deals hit record as innovative drugs draw global interest

Deals reach US$60 billion in first quarter after analysts say Chinese biotech firms have shown substantial technological advancements.

China’s private sector

China’s obesity drug makers take on global giants as Novo Nordisk patent expires

Patent expiry of blockbuster drug opens door for Chinese drug makers to challenge multinationals in booming weight-loss market.

China’s private sector

Rights to antibody drug from China’s Keymed change hands in US acquisition

Sichuan-based Keymed expects to receive up to US$320 million as a result of deal involving its autoimmune disease treatment licensed in 2024.

Gilead Sciences is one of many drug firms facing a revenue gap owing to expiring patents. Photo: Reuters
Made in China 2025

Global drug giants double down on China amid push for self-reliant supply chains

Multinationals are building self-reliant supply chains in China to insulate local markets from potential trade disruptions, say analysts.

AstraZeneca’s booth at the China International Supply Chain Expo in Beijing, July 17, 2025. Photo: EPA
China’s private sector

US reshoring drive casts shadow over China’s contract drug makers, analyst says

Strong order backlogs underpin earnings through 2027, but analysts warn longer-term demand is less certain as US firms reshore production.

Banking & finance

Hong Kong attracts wave of biotech IPO filings amid AI drug research boom

More than 10 pre-profit drug developers are seeking Hong Kong listings as AI-powered biotech platforms draw growing investor interest.

Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement